Google
AMGN Stock Price & Analysis — Amgen Inc (Healthcare >> Drug Manufacturers - General)
AMGN FAQ
What is AMGN's P/E ratio?
Amgen Inc (AMGN) currently trades at a P/E ratio of 24.08.
What is AMGN's ROE?
Amgen Inc reports a Return on Equity (ROE) of 74.80%.
What is AMGN's dividend yield?
Amgen Inc offers a dividend yield of 2.55%.
What is AMGN's Quality Score?
Our AI rates AMGN's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AMGN?
Our AI Timing Score for AMGN is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AMGN belong to?
Amgen Inc is classified under the Healthcare >> Drug Manufacturers - General sector on the NASDAQ exchange
AMGN AI Analysis Summary
Our AI summary for AMGN: Amgen Inc (NASDAQ), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 24.08, ROE of 74.80%, a dividend yield of 2.55%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 407.83
Price
17.81
(4.57%)
Day Change
|
|
|---|
AMGN, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
55% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
1176
|
| Magic Formula Rank by ROE |
1176
|
| Magic Formula Rank by ROIC |
1288
|
| Price | 407.83 |
| PBV / Sector |
18.01 / 7.38
|
| Earning Per Share | 16.94 |
| PE / Sector |
24.08 / 24.11
|
| PEG or PE/Growth / Sector |
1.39 / 0.98
|
| Average 1M Daily Value |
932.10 M
|
| Average 1W Daily Value |
1,313.56 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
54% |
| Ability to Make Profit |
|
75% |
| Return to Investors |
|
12% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:37 |
| Symbol | AMGN |
| Name | AMGEN INC |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NASDAQ |
| Listed Shares | 539.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 210,497.03 / 251,024.73 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
Phone: 805 447 1000
Website: https://www.amgen.com
Employees: 31,500
Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
